Mingxi Lin
Impact in
- Cancer Research top 10%
- NF-κB Signaling Pathways
-
- Natural Compounds in Disease Treatment
Papers in
- Oncology 9
- HER2/EGFR in Cancer Research 4
- Cancer Immunotherapy and Biomarkers 2
-
- Breast Cancer Treatment Studies 3
- NF-κB Signaling Pathways 2
- Co-authors
- Yizi Jin (12 shared papers)Cheng Zeng (3 shared papers)Jian Zhang (3 shared papers)Teng Zhou (3 shared papers)Xinyu Chen (1 shared paper)Xin Shen (1 shared paper)Xiaomin Ye (1 shared paper)Qing Guo (1 shared paper)
In The Last Decade
Mingxi Lin
23 papers receiving 1.4k citations
Mingxi Lin's Hit Papers
Peers
Comparison fields: 5 of 96
- Cancer Research 144
- Complementary and alternative medicine 82
- Immunology 153
- Neurology 59
- Oncology 127
Countries citing papers authored by Mingxi Lin
This map shows the geographic impact of Mingxi Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mingxi Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mingxi Lin more than expected).
Fields of papers citing papers by Mingxi Lin
This network shows the impact of papers produced by Mingxi Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mingxi Lin. The network helps show where Mingxi Lin may publish in the future.
Co-authors
The 25 scholars most cited alongside Mingxi Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | NF-κB in biology and targeted therapy: new insights and translational implications Hit paper breakdown → | 2024 | 1305 |
| 2 | 2020 | 35 | |
| 3 | 2024 | 21 | |
| 4 | 2023 | 20 | |
| 5 | 2020 | 19 | |
| 6 | 2016 | 14 | |
| 7 | 2020 | 9 | |
| 8 | 2020 | 7 | |
| 9 | 2021 | 7 | |
| 10 | 2025 | 6 | |
| 11 | 2025 | 6 | |
| 12 | 2021 | 5 | |
| 13 | 2021 | 4 | |
| 14 | 2022 | 4 | |
| 15 | 2024 | 4 | |
| 16 | 2022 | 2 | |
| 17 | 2025 | 2 | |
| 18 | 1989 | 1 | |
| 19 | Discussion on diabetes mellitus based on ‘spirit, physique, appetite, sleeping, urine and stool' | 2014 | 1 |
| 20 | 2021 | 1 |
About Mingxi Lin
Mingxi Lin is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Infectious Diseases and Genetics, having authored 24 papers that have together received 1.5k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (4 papers), Brain Metastases and Treatment (3 papers), Breast Cancer Treatment Studies (3 papers), SARS-CoV-2 and COVID-19 Research (3 papers), Cancer Immunotherapy and Biomarkers (2 papers), NF-κB Signaling Pathways (2 papers), Advanced Breast Cancer Therapies (2 papers) and RNA Interference and Gene Delivery (1 paper). The work is most often cited by research in Cancer Research (144 citations), Complementary and alternative medicine (82 citations), Immunology (153 citations), Neurology (59 citations) and Oncology (127 citations). Mingxi Lin has collaborated with scholars based in China, Taiwan and Spain. Frequent co-authors include Yizi Jin, Cheng Zeng, Jian Zhang, Teng Zhou, Xinyu Chen, Xin Shen, Xiaomin Ye, Qing Guo, Xichun Hu and Xichun Hu. Their work appears in journals such as Cancer Medicine, Breast Cancer Targets and Therapy, EClinicalMedicine, Life Sciences and International Journal of Legal Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.